# Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

> **NCT00628264** · PHASE2 · TERMINATED · sponsor: **Action Pharma A/S** · enrollment: 75 (estimated)

## Conditions studied

- Cardiac Surgery
- Coronary Artery Bypass Grafting
- Valve Surgery
- Kidney Injury

## Interventions

- **DRUG:** AP214
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00628264
- **Lead sponsor:** Action Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 75 (ESTIMATED)
- **Why stopped:** The study was terminated due to a considerably lower recruitment rate than anticipated
- **Last updated:** 2009-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00628264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00628264, "Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00628264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*